8-K: AdaptHealth Reports Q1 2026 Results, COO Departs

AdaptHealth Corp. announced its first quarter 2026 financial results, highlighting a significant de novo expansion and a $1.1 billion refinancing, alongside the departure of its Chief Operating Officer.

Summary

• AdaptHealth reported Q1 2026 net revenue of $819.8 million, a 5.4% increase from $777.9 million in Q1 2025.
• Organic revenue growth was 9.1%, with increases across all reportable segments.
• The company experienced a net loss attributable to AdaptHealth Corp. of $16.0 million, compared to a net loss of $7.2 million in the prior year.
• Adjusted EBITDA decreased by 5.3% to $121.2 million from $127.9 million.
• Cash flow from operations was $93.7 million, a slight decrease from $95.5 million.
• Free cash flow was negative $27.5 million, a significant decrease from negative $0.1 million in the prior year.
• The company completed a large de novo expansion for a new strategic partner, incurring $12.0 million in elevated labor expenses expected to normalize by Q2 2026.
• A $1.1 billion refinancing of the senior secured credit facility was completed in April 2026, reducing near-term amortization and lowering debt costs.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mixed report. While revenue and organic growth are positive, the increased net loss, decreased Adjusted EBITDA, and significantly negative free cash flow are concerning, despite management's commentary on strategic expansion.

Positives

• Net revenue increased by 5.4% to $819.8 million in Q1 2026.
• Organic revenue growth was strong at 9.1%, demonstrating growth across all segments.
• Completed the largest de novo expansion in the home medical equipment industry, meeting an aggressive go-live schedule.
• Increased registered myApp users by 26% to 412,000, indicating improved digital patient engagement.
• Completed a $1.1 billion refinancing of the senior secured credit facility, reducing near-term debt obligations and lowering the cost of debt.
• Disposition of remaining custom rehabilitation assets further concentrates the portfolio on core Sleep and Respiratory Health businesses.

Negatives

• Net loss attributable to AdaptHealth Corp. widened to $16.0 million in Q1 2026 from $7.2 million in Q1 2025.
• Adjusted EBITDA decreased by 5.3% to $121.2 million from $127.9 million.
• Free cash flow was negative $27.5 million, a significant deterioration from negative $0.1 million in the prior year.
• Incurred $12.0 million in elevated labor expenses due to the large de novo expansion, though a majority is expected to normalize.

Risks

• Potential for ongoing elevated wages and benefits as the company aligns its operating model to new service requirements.
• Risks and uncertainties related to judicial and administrative proceedings or governmental investigations that could interrupt operations or result in adverse judgments.
• Changes in customer preferences, prospects, and competitive conditions in the healthcare sector.
• The company's ability to manage the integration and operational efficiency following the large de novo expansion.

Future Outlook

For fiscal year 2026, AdaptHealth is raising net revenue guidance to $3.45 billion - $3.52 billion and maintaining Adjusted EBITDA guidance of $680 million - $730 million and free cash flow guidance of $175 million - $225 million.

Management Comments

• "The opening months of 2026 have set the stage for what will be a defining year for AdaptHealth," said Suzanne Foster, Chief Executive Officer.
• "We completed the largest de novo expansion in the history of the home medical equipment industry, delivering revenue well ahead of our first quarter guidance, with broad-based organic growth across all four segments."
• "Although we incurred elevated labor costs to execute the transition responsibly, we are already working to optimize the business for our newly attained scale."

Industry Context

StockSavvy.ai notes that AdaptHealth's significant de novo expansion and subsequent labor cost increase, while impacting short-term profitability and free cash flow, are strategic moves to capture market share in the growing healthcare-at-home sector. The company's focus on digital engagement and portfolio concentration aligns with industry trends towards efficiency and specialized care.

Comparison to Industry Standards

• The reported organic revenue growth of 9.1% for Q1 2026 is robust and likely exceeds the average growth rate for many companies in the diversified healthcare services sector, which often sees single-digit growth.
• The negative free cash flow of -$27.5 million is a concern, especially when compared to peers who may be generating positive free cash flow. However, this is attributed to a specific, large-scale expansion project.
• The Adjusted EBITDA margin of 14.8% is a key metric. While lower than the previous year's 16.4%, it remains a significant figure for a company of this scale in the home healthcare space, though it warrants monitoring for normalization.

Management Changes

Legal Proceedings

• The company may be subject to judicial and administrative proceedings or governmental investigations that could interrupt operations or result in adverse judgments, settlements, or fines.

Stakeholder Impact

• Shareholders: Potential negative impact due to increased net loss and decreased Adjusted EBITDA, offset by positive revenue growth and future guidance.
• Employees: Potential for changes in compensation and benefits as the company aligns its operating model post-expansion.
• Creditors: The $1.1 billion refinancing may improve near-term liquidity and reduce debt servicing costs.

Next Steps

• Optimize the business for newly attained scale following the de novo expansion.
• Monitor normalization of elevated labor costs by the end of the second quarter.
• Redeem the Company's 6.125% Senior Notes due 2028 following the call premium expiration in August 2026.

Key Dates

Recommendation

The company shows strong revenue growth and strategic expansion, but the widening net loss, decreased Adjusted EBITDA, and significantly negative free cash flow warrant caution. The upcoming normalization of labor costs and successful integration of the expansion are key factors to monitor. The refinancing is a positive step for liquidity.

Keywords

AdaptHealth, 8-K, Healthcare-at-Home, Home Medical Equipment, Financial Results, Q1 2026, COO Departure, Refinancing